Yonas Belay

Yonas Belay

Auto-generated profile, based on publicly available information

Yonas Belay

Department of Chemical Sciences, University of Johannesburg, Johannesburg, South Africa

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 March 2024 in Scientific Reports
Verified
Journal Article
Open access
PDF file
YBYonas Belay
Yonas Belay
AMAlfred Muller
Alfred Muller
SMShrey Mokoena
Shrey Mokoena
AAAdedapo S. Adeyinka
Adedapo S. Adeyinka
LMLesetja R. Motadi
Lesetja R. Motadi
AOAbel K. Oyebamiji
Abel K. Oyebamiji
A series of novel 1,2,3-triazole and chiral Schiff base hybrids 2–6 were synthesized by Schiff base condensation reaction from pre-prepared parent component of the hybrids (1,2,3-triazole 1) and series of primary chiral amines and their chemical structure were confirmed using NMR and FTIR spectroscopies, and CHN elemental analysis. Compounds 1–6 were evaluated for their anticancer activity against two cancer PC3 (prostate) and A375 (skin) and MRC-5 (healthy) cell lines by Almar Blue assay method. The compounds exhibited significant cytotoxicity against the tested cancer cell lines. Among the tested compounds 3 and 6 showed very good activity for the inhibition of the cancer cell lines and low toxicity for the healthy cell lines. All the compounds exhibited high binding affinity for Androgen receptor modulators (PDB ID: 5t8e) and Human MIA (PDB ID: 1i1j) inhibitors compared to the reference anticancer drug (cisplatin). Structure activity relationships (SARs) of the tested compounds is in good agreement with DFT and molecular docking studies. The compounds exhibited desirable physicochemical properties for drug likeness.

20 April 2023 in Journal of Molecular Structure
Verified
Journal Article
Closed access
YBYonas Belay
Yonas Belay
AMAlfred Muller
Alfred Muller
PLPaballo Leballo
Paballo Leballo
OKOyebamiji A. Kolawole
Oyebamiji A. Kolawole
AAAdedapo Sunday Adeyinka
Adedapo Sunday Adeyinka
LMlesetja Raymond Motadi
lesetja Raymond Motadi

1 February 2019 in Tetrahedron Letters
Verified
Journal Article
Closed access
YBYonas Belay
Yonas Belay
LCLouis-Charl Cloete Coetzee
Louis-Charl Cloete Coetzee
DWD. Bradley G. Williams
D. Bradley G. Williams
AMAlfred Johannes Muller
Alfred Johannes Muller

23 November 2022 in Journal of Molecular Structure
Verified
Journal Article
Closed access
YBYonas Belay
Yonas Belay
AMAlfred Johannes Muller
Alfred Johannes Muller
DNDerek T. Ndinteh
Derek T. Ndinteh
OKOyebamiji A. Kolawole
Oyebamiji A. Kolawole
AAAdedapo Sunday Adeyinka
Adedapo Sunday Adeyinka
TFThierry Y. Fonkui
Thierry Y. Fonkui

12 October 2022 in Electrocatalysis
Verified
Journal Article
Closed access
PDF file
YBYonas Belay
Yonas Belay
AMAlfred Johannes Muller
Alfred Johannes Muller
KMKaushik Mallick
Kaushik Mallick

1 April 2025 in Chemistry & Biodiversity
Verified
Journal Article
Open access
YBYonas Belay
Yonas Belay
AMAlfred Johannes Muller
Alfred Johannes Muller
SSSage Singh
Sage Singh
AAAdedapo Sunday Adeyinka
Adedapo Sunday Adeyinka
LMlesetja Raymond Motadi
lesetja Raymond Motadi
AOAbel kolawole Oyebamiji
Abel kolawole Oyebamiji
Polar substituted Schiff bases and 1,2,3‐triazole hybrids (2–6) were successfully synthesized by Schiff base condensation reaction between the previously synthesized triazole 1 and series of polar substituted amines. The chemical structures of the hybrids were confirmed using spectroscopies (NMR and FTIR), CHN elemental analysis and single‐crystal x‐ray diffraction analysis. The compounds were evaluated for their antiproliferative activity against two cancer cells, PC3 (prostate) and MCF7 (breast) cell lines, using the alamarBlue assay method, and camptothecin was employed as a standard. All the compounds exhibited good activity for the proliferation of the cancer cell lines compared to the standard, and their activity is concentration‐dependent. Compounds 1, 2, 4 and 5 exhibited good caspase activity with relevant dosages that inhibited 50% (IC50) in prostate cancer cells. All the compounds exhibited high binding affinity for human 3‐alpha hydroxysteroid dehydrogenase type 3 (PDB ID: 4xo6) and Androgen receptor (PDB ID: 2Q7K) inhibitors compared to the reference anticancer drug (camptothecin). Structure–activity relationships (SARs) of the tested compounds are in good agreement with DFT and molecular docking studies. ADMET analysis was used to predict the pharmacokinetics, pharmacodynamics and toxicology of the compounds, and it proved that the compounds exhibited desirable physicochemical properties for drug likeness.